But data on Covid DOES matter. The pathology of the effect of Leronlimab on the immune system matters. There is a reason the why an HIV drug was effective against critical Covid 19 and this pathology does matter when looking into other diseases. That's why Long Haulers was so interesting, lots of different pathology rolled into one with so many symptoms.

But Drano, you are also right, this data doesn't matter so much now to investors as much as to researchers and therefore future partners. They probably have the data and Cyrus has made the investment decision that Covid is too difficult and expensive a market to break into.

So my take on the CC, very positive. CA knows exactly what he is doing, very positive on the future. This CC appeared to me to be for the case against Amarex as Chazzledazzle said, dropping the BLA makes for a stronger case.